Form 8-K Epizyme, Inc. For: Nov 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
RBC Affirms Epizyme (EPZM) at 'Outperform' as Ttazemetostat Enrollment Continues
November 9, 2015 12:43 PM ESTRBC Captial affirms Epizyme (Nasdaq: EPZM) at Outperform with a price target of $39 following Q3 results and update issued earlier.
Analyst Simos Simeonidis noted the following:
Enrollment continues in 150-patient Phase II study in NHL in Europe: On their 3Q15 earnings call this morning, management stated that plans remain on track for tazemetostat's Phase II programs. Patients are currently being enrolled in the 5-arm,... More
